The application of quercetin in liposomal form for optimization of metabolic therapy of coronary artery disease.

Prof. O.M. Korzh

Kharkiv Medical Academy of Postgraduate Education, Department of General Practice — Family Medicine

The study of the clinical efficacy and safety of the dietary supplement L-Quercet as part of the complex therapy of patients with coronary artery disease with stable angina of II functional class, taking into account their effect on the clinical course of the disease, exercise tolerance and functional state of the endothelium. It has been shown that the inclusion of L-Quercet in the complex therapy in patients with stable angina leads to an improvement in the clinical course of angina pectoris, allows to significantly increase exercise tolerance and the quality of life of patients. The use of L-Quercet improves the indicators of endothelial function according to the results of the cuff test, which is one of the main factors in the prevention of the development and progression of atherosclerosis and coronary artery disease, and also causes an increase in the effectiveness of antianginal pharmacotherapy.

Key Words: quercetin, coronary artery disease, endothelium.

https://dx.doi.org/10.15407/internalmed2021.02.118

Download.PDF (rus)

Cite:

  1. Корж, А.Н. Применение кверцетина в липосомальной форме для оптимизации метаболической терапии ишемической болезни сердца / Східноєвропейський журнал внутрішньої та сімейної медицини. – 2021. – № 2. – С. 118-123. doi: 15407/internalmed2021.02.118
  2. Korzh OM. Primenenie kvercetina v liposomal’noj forme dlya optimizacii metabolicheskoj terapii ishemicheskoj bolezni serdca. [The application of quercetin in liposomal form for optimization of metabolic therapy of coronary artery disease]. Shidnoevr. z. vnutr. simejnoi med. 2021;2:118-123. Russian. doi: 10.15407/internalmed2021.02.118

References:

  1. Akimov AG, Polumiskov VJu. Perspektivy primenenija miokardial’nyh citoprotektorov v kardiologicheskoj praktike. Terra medica nova. 2005;4: 6—9. Russian
  2. Drapkina OM, Kozlova EI. Novye sposoby optimizacii protivoishemicheskoj terapii. Rossijskij kardiologicheskij zhurnal 2010; 1:82-84. Russian
  3. Zolotareva NA, Medjanka JuS. Izuchenie tolerantnosti k fizicheskoj nagruzke pri sochetannom ispol’zovanii meksikora i magnitoterapii u bol’nyh stabil’noj stenokardiej naprjazhenija .Ukr. med. chasopis. 2011;5 (85):71—73. Russian
  4. Kotljarov AA, Aroslankina OI. Vlijanie metabolicheskoj terapii meksikorom na techenie bradiaritmij. Med. sovet. 2007 ;4:71—75. Russian
  5. Medjanka JuS. Vlijanie meksikora na lipidnyj spektr krovi u bol’nyh stabil’noj stenokardiej naprjazhenija. Klіnіchna ta eksperiment. patologіja. 2011;2 (36 ch. 2): 65—68. Russian
  6. Shljahto EV, Galagudza ММ, Nifontov EM. Metabolizm miokarda pri hronicheskoj serdechnoj nedostatochnosti i sovremennye vozmozhnosti metabolicheskoj terapii. Serdechnaja nedostatochnost’. 2005;4:148-155. Russian
  7. Amosova EN. Metabolicheskaja terapija povrezhdenij miokarda, obuslovlennogo ishemiej: novyj podhod k lecheniju ishemicheskoj bolezni serdca i serdechnoj nedostatochnosti Ukr. kardiol. zhurn. 2000;4:86—92. Russian
  8. Hlebodarov FE, Tjurikov PJu, Mihin VP. Disfunkcija sosudistogo jendotelija i ee korrekcija citoprotektorami u bol’nyh stabil’noj stenokardiej naprjazhenija i arterial’noj gipertoniej. Rossijskij kardiologicheskij zhurnal. 2009; 6 (80):34-38. Russian
  9. Lapshina L, Zolotaikina V. Oxidative stress in acute heart failure and role of antioxidant quercetine in its correction. International medical journal. 2009;15No3(59):45-51.
  10. Adamek A, Jung S, Dienesch C, Laser M, Ertl G, Bauersachs J, Frantz S. Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. European Journal of Pharmacology. 2007;571(1):51-54. http://dx.doi.org/10.1016/j.ejphar.2007.05.040
  11. Chekman IS, Gorchakova NA., Francuzova SB Kardioprotektory. Chekman IS, editor. K.; 2005. 204 р. Russian
  12. Sergienko IV, Bugrij ME, Balahonova TV, Tkachev GA, Sergienko VB. Vozmozhnost’ ispol’zovanija korrektorov metabolizma v lechenii pacientov s ishemicheskoj bolezn’ju serdca i nedostatochnost’ju krovoobrashhenija. Racional’naja farmakoterapija v kardiologii .2007; T. 3.;4: 25-31. Russian https://doi.org/10.20996/1819-6446-2007-3-4-25-31
  13. Grigor’eva AS., Kacaj AG., Kohanovich NF., Prohorov VV, Stadnichenko AV, Shvec VI, Krasnopol’skij JuM. Real’naja nanofarmakologija: 25 let razrabotki i primenenija liposomal’nyh lekarstvennyh preparatov v Ukraine. Farmakom. 2016; 1: 41-45. Russian
  14. Hromov AS. Liposomal’nye preparaty — realizacija nanotehnologij v medicine. Farmakologіja ta lіkars’ka toksikologіja. 2016; 2(48):14-23. Russian
  15. Svistel’nik AV, Hanin AL. Liposomal’nye lekarstvennye preparaty: vozmozhnosti i perspektivy. Medicina v KuzbaseT. 2014;13( 2). Russian